3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Thyroid Neoplasms
2
Lung Neoplasms
2
Thoracic Neoplasms
1
Solid Tumors
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Bronchial Diseases
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Adenocarcinoma
1
Interventions
Etoposide
7
Cisplatin
7
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Paclitaxel
3
Carboplatin
3
Bleomycin
3
Automobiles
3
pembrolizumab
2
etoposide phosphate
2
Vorinostat
2
Sirolimus
2
Mesna
2
Ifosfamide
2
Drug Therapy
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
tozuleristide
1
sodium thiosulfate
1
repotrectinib
1
pralsetinib
1
pegfilgrastim
1
lutetium Lu 177 dotatate
1
durvalumab
1
cabozantinib
1
Watchful Waiting
1
Teniposide
1
Surveys and Questionnaires
1
Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
pralsetinib
×
1 year
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts